Quantbot Technologies LP Acquires New Shares in Pfizer Inc. $PFE

Key Points

• Quantbot Technologies LP has acquired a new stake of 85,095 shares in Pfizer Inc., valued at approximately $2,156,000 during the first quarter.
• Pfizer reported a quarterly earnings result with an EPS of $0.78, surpassing the consensus estimate by $0.20, alongside a revenue of $14.65 billion, exceeding expectations.
• The biopharmaceutical company announced a quarterly dividend of $0.43, reflecting a dividend yield of 6.7% and a payout ratio of 91.49%.

Quantbot Technologies LP acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 85,095 shares of the biopharmaceutical company's stock, valued at approximately $2,156,000.

Several other large investors have also bought and sold shares of the business. Allen Wealth Management LLC boosted its stake in Pfizer by 6.1% in the first quarter. Allen Wealth Management LLC now owns 92,516 shares of the biopharmaceutical company's stock valued at $2,344,000 after buying an additional 5,280 shares in the last quarter. Granite Harbor Advisors Inc. acquired a new stake in Pfizer in the first quarter valued at about $247,000. Northern Trust Corp boosted its stake in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Brooklyn Investment Group lifted its stake in shares of Pfizer by 25.8% in the 1st quarter. Brooklyn Investment Group now owns 16,020 shares of the biopharmaceutical company's stock valued at $406,000 after acquiring an additional 3,283 shares during the last quarter. Finally, Prospector Partners LLC lifted its stake in shares of Pfizer by 60.9% in the 1st quarter. Prospector Partners LLC now owns 142,455 shares of the biopharmaceutical company's stock valued at $3,610,000 after acquiring an additional 53,900 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group upped their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Trading Up 1.3%

NYSE PFE opened at $25.7060 on Friday. The business's 50-day moving average price is $24.68 and its two-hundred day moving average price is $24.42. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a market capitalization of $146.15 billion, a PE ratio of 13.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.